spacer
home > ict > autumn 2016 > deliverapp
PUBLICATIONS
International Clinical Trials

Deliverapp

“Over the past few decades,” the WHO said in its landmark 2003 report ‘Adherence to long-term therapies: Evidence for action’, “we have witnessed several phases in the development of approaches aimed at ensuring that patients continue therapy for chronic conditions for long periods of time. Initially, the patient was thought to be the source of the ‘problem of compliance.’ Later, the role of the providers was also addressed. Now we acknowledge that a systems approach is required. The idea of compliance is associated too closely with blame, be it of providers or patients, and the concept of adherence is a better way of capturing the dynamic and complex changes required of many players over long periods to maintain optimal health in people with chronic diseases.”

Research indicates that a patient’s improved medication adherence is directly linked to favourable treatment results for a variety of chronic conditions, including multiple sclerosis and diabetes. Yet patient compliance with chronic medication therapies is remarkably low – the WHO estimates it to be at 50% internationally (1). Noncompliance leads to poor clinical outcomes, lost revenue for pharmaceutical companies worldwide, and increased costs for many healthcare financial stakeholders – including patients themselves.

For individuals with incurable, but controllable chronic conditions, innovative biologic therapies have the potential to improve their quality of life by not only reducing symptoms, but also offering independence enabled by at-home treatment. However, as biologic therapies are often administered in higher viscosities and higher injected volumes, it creates challenges for the entire supply chain as we struggle to ensure appropriate self-administration by patients consistently and effectively, without the expert oversight of their healthcare provider. Combine this with growing regulatory scrutiny to ensure the quality and efficacy of therapeutic offerings throughout their lifecycle, and the industry finds itself in a new, increasingly patientcentric wave of drug delivery.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Chris Evans is Vice President at West Pharmaceutical Services and has been in product development for more than 20 years, primarily in healthcare packaging and device development. He graduated from the University of Maryland in Bio/ Chemistry and has, since then, worked mostly on the ‘front-end’ of innovation. Having been with West for eight years, Chris is now responsible for new product and technology development, focusing on device usability and enhancing the patient experience.
spacer
Chris Evans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement